UMCG Studies Show Low-Dose Digoxin Cuts Heart Failure Hospitalizations by 25%
Updated
Updated · SciTechDaily · May 21
UMCG Studies Show Low-Dose Digoxin Cuts Heart Failure Hospitalizations by 25%
2 articles · Updated · SciTechDaily · May 21
Three UMCG-led studies found low-dose digoxin reduced heart-failure hospital admissions by about 25%, adding evidence that the centuries-old drug could complement the current four-drug standard.
A randomized trial of 1,000 patients at 43 Dutch centers showed a 19% drop in cardiovascular death and worsening heart failure, but that result did not reach statistical significance until researchers pooled it with two earlier studies.
A follow-up study of about 600 participants also found more early complications after stopping digoxin: among 288 patients who discontinued treatment, 14 were hospitalized or died within six weeks.
Digoxin costs under €0.10 a day versus several euros for newer therapies, and researchers said the low-dose regimen appeared safe, simple to use and potentially relevant for future treatment guidelines.
Heart failure affects more than 500,000 people in the Netherlands, yet only about 15% of patients currently receive digoxin after its use declined with the rise of newer drugs.
A once-risky heart drug is back in favor. What new evidence makes it a safe option now?
This heart failure drug costs just cents. Why is it suddenly being called a breakthrough?
Low-Dose Digoxin Reduces Heart Failure Hospitalizations: Landmark UMCG and DECISION Trial Findings Signal a Digitalis Renaissance
Overview
This report highlights how concerns about digoxin’s toxicity and the rise of newer heart failure treatments led to a decline in its use, despite early evidence from the DIG trial showing reduced hospitalizations but no effect on mortality. Persistent worries that earlier studies used doses that were too high fueled these concerns. Recently, the UMCG’s involvement in the DECISION trial addressed a major gap by providing the first randomized, prospective evidence that low-dose digoxin is both effective and safe. These findings support a renewed role for carefully monitored, low-dose digoxin in modern heart failure management.